Featured
-
Business Wire India If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphoma Application supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or…
Highlighted
-
Business Wire India If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle…
-
Business Wire India Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including…
-
Business Wire India Tech Data Advanced Private Limited, a TD SYNNEX company, today announced a strategic partnership with SISA, a global cybersecurity company focused on…
-
Propshop’s evolution from a traditional exhibition stand contractor into a globally recognized exhibition solutions partner serving brands across multiple industries and international markets MUMBAI, India,…
-
LIMA, Nov. 5, 2026 /PRNewswire/ — The gastronomic world gathered in Lima, Peru for the unveiling of The 50 Best Restaurants 2026 list, sponsored by S.Pellegrino…
-
TravelSure extends Dohop’s rebooking support to disrupted direct flights, giving travellers peace of mind and travel sellers a way to deliver better support during disruption…